Related Articles

Bronchodilating Drugs for Chronic Obstructive Pulmonary Disease: Current Status and Future Trends.

J Med Chem. 2015 Jan 14;

Authors: Montuschi P, Ciabattoni G

Abstract
Inhaled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and long-acting beta2-adrenoreceptor agonists (LABA), are the mainstay of pharmacological treatment of stable chronic obstructive pulmonary disease (COPD). Among approved LAMA, tiotropium bromide, glycopyrronium bromide and umeclidinium bromide, are administered once daily, whereas aclidinium bromide is administered every 12 hours. New LAMA are under development for COPD. Among the approved LABA, indacaterol has a 24-h duration of action, whereas salmeterol and formoterol require twice-daily administration. New once-daily LABA, including vilanterol, olodaterol, milveterol, carmoterol, and abediterol, are in development. LAMA/LABA fixed dose combinations (FDC) provide the convenience of two bronchodilators with different mechanism of action in a single inhaler. Indacaterol/glycopyrronium, umeclidinium/vilanterol and olodaterol/tiotropium FDC, have been approved or are under approval and are likely to become a standard pharmacological strategy for COPD. Dual-pharmacology compounds, combining muscarinic antagonism and beta2-agonism (MABA) in a single molecule, potentially provide additive or synergistic bronchodilation over either inhaled antimuscarinic or beta2-agonist monotherapy.

PMID: 25587755 [PubMed - as supplied by publisher]